ArticleCureus2026
Distal Renal Tubular Acidosis as a Renal Manifestation of Sjögren's Syndrome: A Case Report.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Distal renal tubular acidosis (dRTA) is a rare but recognized renal complication of Sjögren's syndrome (SS), often resulting from autoimmune-mediated damage to acid-base transporters in the distal nephron. It commonly presents with electrolyte abnormalities including hypokalemia and metabolic acidosis. A 47-year-old woman with chronic kidney disease presented with recurrent hypokalemia, mild proteinuria, and sicca symptoms. Workup revealed non-anion gap metabolic acidosis, a positive urine anion gap, and renal potassium wasting consistent with dRTA. Autoimmune testing showed a high-titer ANA (1:1280) and elevated SSA (>8.0), confirming SS. Renal biopsy revealed mild interstitial fibrosis and glomerulosclerosis without evidence of tubulointerstitial nephritis or immune complex deposition. This finding supports prior evidence that SS-associated dRTA may occur secondary to functional tubular defects involving distal nephron transporters, even in the absence of overt inflammatory histologic changes. Acid-base disturbances improved with potassium and bicarbonate supplementation. This case highlights that significant tubular dysfunction in SS may occur despite minimal or absent histologic evidence of tubulointerstitial nephritis. dRTA in SS may result from autoimmune targeting of distal nephron transporters such as H⁺-ATPase and anion exchanger 1. Early recognition and supportive treatment are essential to prevent complications including nephrolithiasis, progressive kidney dysfunction, and life-threatening hypokalemia. SS should be considered in patients presenting with unexplained dRTA, and timely correction of electrolyte abnormalities is critical to optimizing outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.